1 – 100 of 102
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Cost-effectiveness of specialised manual therapy versus orthopaedic care for musculoskeletal disorders : long-term follow-up and health economic model
(
- Contribution to journal › Article
-
Mark
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life
(
- Contribution to journal › Article
- 2021
-
Mark
Coronaviruset i Sverige. "Nedstängningar gör mer skada än nytta"
2021) In Svenska Dagbladet(
- Contribution to specialist publication or newspaper › Newspaper article
-
Mark
Projected economic burden of pancreatic cancer in Sweden in 2030
(
- Contribution to journal › Article
-
Mark
The Value of a New Diagnostic Test for Prostate Cancer : A Cost-Utility Analysis in Early Stage of Development
(
- Contribution to journal › Article
-
Mark
Swedish guidelines for device-aided therapies in Parkinson's disease —Economic evaluation and implementation
(
- Contribution to journal › Article
- 2019
-
Mark
Dread and Risk Elimination Premium for the Value of a Statistical Life
(
- Contribution to journal › Article
- 2018
-
Mark
Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype
(
- Contribution to journal › Article
- 2017
-
Mark
Acute biliary pancreatitis: focus on recurrence rate and costs when current guidelines are not complied
(
- Contribution to journal › Article
- 2016
-
Mark
Preferences for improvements in attributes associated with basal insulin : a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden
(
- Contribution to journal › Article
-
Mark
Dread and Risk Elimination Premium for the Value of a Statistical Life
2016) In Working Papers(
- Working paper/Preprint › Working paper
-
Mark
Measuring the End of Life Premium in Cancer using Individual ex ante Willingness to Pay
2016) In Working Papers(
- Working paper/Preprint › Working paper
-
Mark
Value of a QALY and VSI Estimated with the Chained Approach
(
- Working paper/Preprint › Working paper
-
Mark
Chained Approach vs Contingent Valuation for Estimating the Value of Risk Reduction
(
- Working paper/Preprint › Working paper
-
Mark
Betalningsviljan för att minska risken för icke-dödliga och dödliga skador i samband med vägtrafikolyckor – en pilotstudie med jämförelse av CV och kedje-ansats
2016) In IHE Rapport(
- Book/Report › Report
-
Mark
Betalningsviljan för att minska risken för icke-dödliga och dödliga skador i samband med vägtrafikolyckor – en studie med kedje-ansats
2016) In IHE Rapport(
- Book/Report › Report
-
Mark
Value of treatment in clinical trials versus the real world : the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden
(
- Contribution to journal › Article
-
Mark
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
(
- Contribution to journal › Article
-
Mark
Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe
(
- Contribution to journal › Article
- 2015
-
Mark
The End of the International Reference Pricing System?
2015) In Applied Health Economics and Health Policy(
- Contribution to journal › Article
-
Mark
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
(
- Contribution to journal › Article
-
Mark
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
(
- Contribution to journal › Article
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
- 2014
-
Mark
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
(
- Contribution to journal › Article
-
Mark
Willingness to pay for a new drug delivery in Parkinson patients.
(
- Contribution to journal › Article
-
Mark
Costs and outcomes of an exercise referral programme - A 1-year follow-up study.
(
- Contribution to journal › Article
-
Mark
Obesity and Surgical Treatment - A Cost-Effectiveness Assessment for Sweden
(
- Contribution to journal › Article
-
Mark
Costs and Utilities of Manual Therapy and Orthopedic Standard Care for Low Prioritized Orthopedic Outpatients of Working Age: A Cost Consequence Analysis.
(
- Contribution to journal › Article
-
Mark
Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
(
- Contribution to journal › Article
- 2013
-
Mark
Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital.
(
- Contribution to journal › Article
-
Mark
Målriktad behandling av bröstcancer
2013)(
- Other contribution › Miscellaneous
-
Mark
A Candidate Gene Approach to ANCA-Associated Vasculitis Reveals Links to the C3 and CTLA-4 Genes but not to the IL1-Ra And Fcγ-RIIa Genes.
(
- Contribution to journal › Article
-
Mark
Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature.
(
- Contribution to journal › Article
-
Mark
Acute pancreatitis - costs for healthcare and loss of production.
(
- Contribution to journal › Article
-
Mark
Medicinska framsteg i behandling av kronisk myeloisk leukemi
2013)(
- Other contribution › Miscellaneous
- 2012
-
Mark
A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
(
- Contribution to journal › Article
-
Mark
Budget impact analysis of surgical treatment for obesity in sweden.
(
- Contribution to journal › Article
-
Mark
Drug and treatment costs in Parkinson's disease patients in Sweden.
(
- Contribution to journal › Article
-
Mark
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
(
- Contribution to journal › Article
-
Mark
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
(
- Contribution to journal › Article
-
Mark
Societal Value of Stem Cell Therapy in Stroke - A Modeling Study.
(
- Contribution to journal › Article
-
Mark
Hälsoekonomiska modeller vid diabetes: ett hjälpmedel för klinisk forskning och behandlingsval
(
- Contribution to specialist publication or newspaper › Specialist publication article
- 2011
-
Mark
Missbrukets ekonomiska börda i Sverige
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Värdet av nya läkemedel: en förstudie
2011)(
- Contribution to conference › Paper, not in proceeding
-
Mark
Practical issues in handling data input and uncertainty in a budget impact analysis
(
- Contribution to journal › Article
-
Mark
Acquisition cost of dispensed drugs in individuals with multiple medications A register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis Productivity Gain Based on Direct Measurement of Work Capacity before and after 1 Year of Treatment
(
- Contribution to journal › Article
- 2010
-
Mark
The Value of Informal Caregiver Time for Psychotic Illness
(
- Contribution to journal › Article
-
Mark
Willingness to pay for health improvements of physical activity on prescription.
(
- Contribution to journal › Article
-
Mark
Vilken betysdelse har hälsoekonomi vid prioriteringar? Ett experiment bland beslutsfattare och en analys av faktiska prioriteringar.
2010)(
- Book/Report › Report
-
Mark
A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations.
(
- Contribution to journal › Article
- 2009
-
Mark
Costs associated with sharps injuries in the Swedish health care setting and potential cost savings from needle-stick prevention devices with needle and syringe.
(
- Contribution to journal › Article
-
Mark
Viktigt hålla fast vid principen om värdebaserad prissättning av läkemedel.
(
- Contribution to journal › Article
-
Mark
Physical activity on prescription (PAP): Costs and consequences of a randomized, controlled trial in primary healthcare.
(
- Contribution to journal › Article
- 2008
-
Mark
The Swedish cost burden of overweight and obesity - Evaluated with the PAR approach and a statistical modelling approach
(
- Contribution to journal › Article
-
Mark
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
(
- Contribution to journal › Article
-
Mark
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
(
- Contribution to journal › Article
- 2007
-
Mark
Cost-effectiveness analysis of treatment with epoietin-alpha for patients with anaemia due to renal failure: The case of Sweden.
(
- Contribution to journal › Article
-
Mark
Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden
(
- Contribution to journal › Article
- 2006
-
Mark
En blodtransfusion i Sverige - så mycket kostar den samhället
(
- Contribution to journal › Article
-
Mark
Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
(
- Contribution to journal › Article
-
Mark
Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.
(
- Contribution to journal › Article
- 2005
-
Mark
Reimbursement and clinical guidance for pharmaceuticals in Sweden Do health-economic evaluations support decision making?
(
- Contribution to journal › Article
-
Mark
Screening for congenital cataracts: A cost-consequence analysis of eye examination at maternity wards in comparison to well-baby clinics
(
- Contribution to journal › Article
-
Mark
Local Treatment Pattern Versus Trial-based Data: A Cost-effectiveness Analysis of Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis in Sweden.
(
- Contribution to journal › Article
-
Mark
Alport syndrome caused by inversion of a 21 Mb fragment of the long arm of the X-chromosome comprising exon 9 through 51 of the COL4A5 gene
(
- Contribution to journal › Article
-
Mark
Alport syndrome in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Obesity, survival, and hospital costs-findings from a screening project in sweden.
(
- Contribution to journal › Article
-
Mark
Den samhällsekonomiska nyttan av cykeltrafikinvesteringar - Förbättring av beslutsunderlag
2005) In Naturvårdsverket Rapport(
- Book/Report › Report
-
Mark
Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in sweden: comparative analysis of drug utilization, costs, and hematologic response.
(
- Contribution to journal › Article
- 2004
-
Mark
Valuing Reductions in the Risk of Traffic Accidents Based on Empirical Studies in Sweden
2004)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Patients with Goodpasture's disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen {alpha}3 chain.
(
- Contribution to journal › Article
- 2003
-
Mark
Long-term follow-up and consequences for severe road traffic injuries - treatment costs and health impairment in Sweden in the 1960s and the 1990s
(
- Contribution to journal › Article
-
Mark
Vilken hälsoekonomisk information behövs för att sätta pris och ge subventioner?
(
- Contribution to specialist publication or newspaper › Newspaper article
-
Mark
Health-health analysis - An alternative method for economic appraisal of health policy and safety regulation Some empirical Swedish estimates
(
- Contribution to journal › Article
-
Mark
The cost of treating pancreatic cancer--a cohort study based on patients' records from four hospitals in Sweden.
(
- Contribution to journal › Article
-
Mark
Health-Health Analysis - An Alternative Method for Economic Appraisal of Health Policy and Safety Regulation - Some Swedish Estimates
(
- Contribution to journal › Article
-
Mark
X-linked Alport syndrome: Natural history and genotype-phenotype correlations in girls and women belonging to 195 families: A "European community Alport syndrome concerted action" study
(
- Contribution to journal › Article
- 2002
-
Mark
Pris, subvention och läkemedel - användning av hälsoekonomiska utvärderingar
2002)(
- Book/Report › Report
-
Mark
International comparison of costs of a fatal casualty of road accidents in 1990 and 1999
(
- Contribution to journal › Article
-
Mark
Svåra ställningstaganden för pris- och subventioneringsnämnd
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Hälsoekonomisk utvärdering vid rekommendation av läkemedel
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Costs per Fatal Casualty in Traffic Accidents - an International Comparison of Values used in Traffic Planning
(
- Contribution to journal › Article
-
Mark
Kommunalekonomiska konsekvenser till följd av trafikolyckor : en åttaårsuppföljning av långvariga trafikskador
2002) In Bulletin 208 / 3000(
- Book/Report › Report
-
Mark
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
(
- Contribution to journal › Article
- 2000
-
Mark
Värdet av att minska risken för vägtrafikskador : beräkning av riskvärden för dödliga, genomsnittligt våra och lindriga skador med Contingent Valuation metoden
2000) In Bulletin 183 / 3000(
- Book/Report › Report
- 1999
-
Mark
Läkemedelskostnaderna
1999)(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Skattning av riskvärden och dödsfallsekvivalenter i vägtrafiken med hjälp av conjoint analysis, risk-risk trade off och standard gamble metoderna : en pilotundersökning
1999) In Bulletin 182 / 3000(
- Book/Report › Report
-
Mark
Värdering av icke-dödliga skador till följd av trafikolyckor. Arbetsrapport 4. Skadade registrerade på Lunds sjukhus
1999) In 7177 / 7000(
- Book/Report › Report
- 1998
-
Mark
Läkemedelskostnaderna
1998)(
- Book/Report › Report
-
Mark
Värdering av icke-dödliga skador till följd av trafikolyckor. Arbetsrapport 3. Skadade registrerade på Karlskronas sjukhus
1998) In 7176 / 7000(
- Book/Report › Report
- 1997
-
Mark
Kostnader för vägtrafikolyckor i Sverige och värdering av riskreduktioner - en översikt
1997) In Bulletin 144 / 3000(
- Book/Report › Report
-
Mark
Värdet av minskad risk för katastrofer
1997) In 3128 / 3000(
- Book/Report › Report
- 1996
-
Mark
Värdering av icke-dödliga skador till följd av trafikolyckor. Arbetsrapport 1. Skadade registrerade på Lidköpings sjukhus
1996) In 7150 / 7000(
- Book/Report › Report
- 1995
-
Mark
Vilka riskvärden (f.d. humanvärden) bör användas i investeringskalkyler i trafiken?
1995) In Bulletin 128 / 3000(
- Book/Report › Report
-
Mark
Revidering av vägverkets olyckskostnader - en uppräkning till 1997 års priser
1995) In 7141 / 7000(
- Book/Report › Report
-
Mark
Värdet av att minska risken för icke-dödliga trafikskador
1995) In 3101 / 3000(
- Book/Report › Report
- 1994
-
Mark
Minirondeller i Växjö - en ekonomisk utvärdering
1994) In Bulletin 121 / 3000(
- Book/Report › Report
- 1991
-
Mark
The value of risk reduction: results of a swedish sample survey.
1991) In 3075 / 3000(
- Book/Report › Report